Cancer Immunotherapy Strategies That Target the CGAS-STING Pathway

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Nov 10

PMID 36353640

Authors

Zhuoying Tian

Yue Zeng

Yurong Peng

Junqi Liu

Fang Wu

Affiliations

Soon will be listed here.

Abstract

Activation of the cGAS-STING pathway by cytoplasmic DNA induces the production of Type-1 interferons. Recent advances in research suggest that the cGAS-STING pathway is involved in different parts of the cancer-immunity cycle (CIC) to promote or suppress antitumor immune responses. Combination therapy of STING agonists has made certain progress in preclinical as well as clinical trials, but the selection of combination therapy regimens remains a challenge. In this review, we summarize the role of the cGAS-STING in all aspects of CIC, and focus on the combination immunotherapy strategies of STING agonists and current unsolved challenges.

Citing Articles

Targeted intra-tumoral hyperthermia using uniquely biocompatible gold nanorods induces strong immunogenic cell death in two immunogenically 'cold' tumor models.

Kennedy B, Noftall E, Dean C, Roth A, Clark K, Rowles D Front Immunol. 2025; 15:1512543.

PMID: 39872527 PMC: 11769938. DOI: 10.3389/fimmu.2024.1512543.

Differential Response to Local Stimulator of Interferon Genes Agonist Administration in Tumors with Various Stimulator of Interferon Genes Statuses.

Drzyzga A, Czapla J, Matuszczak S, Lasut-Szyszka B, Cichon T, Pilny E Cancers (Basel). 2025; 17(2.

PMID: 39857957 PMC: 11763682. DOI: 10.3390/cancers17020175.

A central role of stimulator of interferon genes' adaptor protein in defensive immune response.

Kaushal A Immunol Res. 2025; 73(1):39.

PMID: 39836303 DOI: 10.1007/s12026-024-09587-1.

cGAS-STING signaling pathway in lung cancer: Regulation on antitumor immunity and application in immunotherapy.

Wu J, Chen Y, Xie M, Yu X, Su C Chin Med J Pulm Crit Care Med. 2025; 2(4):257-264.

PMID: 39834588 PMC: 11742360. DOI: 10.1016/j.pccm.2024.11.001.

Targeting STING signaling for the optimal cancer immunotherapy.

Xu Y, Xiong Y Front Immunol. 2024; 15:1482738.

PMID: 39450170 PMC: 11500076. DOI: 10.3389/fimmu.2024.1482738.

References

Depil S, Duchateau P, Grupp S, Mufti G, Poirot L . 'Off-the-shelf' allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020; 19(3):185-199. DOI: 10.1038/s41573-019-0051-2. View

Chen R, Du J, Zhu H, Ling Q . The role of cGAS-STING signalling in liver diseases. JHEP Rep. 2021; 3(5):100324. PMC: 8340306. DOI: 10.1016/j.jhepr.2021.100324. View

Lohard S, Juin P, Barille-Nion S . Mitotic stress-induced secretome primes cancer cells to apoptosis and maximizes paclitaxel response in breast tumors when combined with BCL-xL-targeting BH3 mimetics. Mol Cell Oncol. 2020; 7(3):1735912. PMC: 7199744. DOI: 10.1080/23723556.2020.1735912. View

Da Y, Liu Y, Hu Y, Liu W, Ma J, Lu N . STING agonist cGAMP enhances anti-tumor activity of CAR-NK cells against pancreatic cancer. Oncoimmunology. 2022; 11(1):2054105. PMC: 8967397. DOI: 10.1080/2162402X.2022.2054105. View

McLaughlin M, Patin E, Pedersen M, Wilkins A, Dillon M, Melcher A . Inflammatory microenvironment remodelling by tumour cells after radiotherapy. Nat Rev Cancer. 2020; 20(4):203-217. DOI: 10.1038/s41568-020-0246-1. View

Huang X, Tang T, Zhang G, Liang T . Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development. Mol Cancer. 2021; 20(1):50. PMC: 7938044. DOI: 10.1186/s12943-021-01342-6. View

Mohamed E, Sierra R, Trillo-Tinoco J, Cao Y, Innamarato P, Payne K . The Unfolded Protein Response Mediator PERK Governs Myeloid Cell-Driven Immunosuppression in Tumors through Inhibition of STING Signaling. Immunity. 2020; 52(4):668-682.e7. PMC: 7207019. DOI: 10.1016/j.immuni.2020.03.004. View

Sceneay J, Goreczny G, Wilson K, Morrow S, DeCristo M, Ubellacker J . Interferon Signaling Is Diminished with Age and Is Associated with Immune Checkpoint Blockade Efficacy in Triple-Negative Breast Cancer. Cancer Discov. 2019; 9(9):1208-1227. PMC: 11167954. DOI: 10.1158/2159-8290.CD-18-1454. View

Yang T, Xiao H, Liu X, Wang Z, Zhang Q, Wei N . Vascular Normalization: A New Window Opened for Cancer Therapies. Front Oncol. 2021; 11:719836. PMC: 8406857. DOI: 10.3389/fonc.2021.719836. View

10.

Marcus A, Mao A, Lensink-Vasan M, Wang L, Vance R, Raulet D . Tumor-Derived cGAMP Triggers a STING-Mediated Interferon Response in Non-tumor Cells to Activate the NK Cell Response. Immunity. 2018; 49(4):754-763.e4. PMC: 6488306. DOI: 10.1016/j.immuni.2018.09.016. View

11.

Lv M, Chen M, Zhang R, Zhang W, Wang C, Zhang Y . Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy. Cell Res. 2020; 30(11):966-979. PMC: 7785004. DOI: 10.1038/s41422-020-00395-4. View

12.

Vieira R, Nascimento M, Noronha I, Vasconcelos J, Benvenuti L, Barber G . STING Signaling Drives Production of Innate Cytokines, Generation of CD8 T Cells and Enhanced Protection Against Infection. Front Immunol. 2022; 12:775346. PMC: 8795786. DOI: 10.3389/fimmu.2021.775346. View

13.

Xu N, Palmer D, Robeson A, Shou P, Bommiasamy H, Laurie S . STING agonist promotes CAR T cell trafficking and persistence in breast cancer. J Exp Med. 2020; 218(2). PMC: 7780733. DOI: 10.1084/jem.20200844. View

14.

Sterner R, Sterner R . CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021; 11(4):69. PMC: 8024391. DOI: 10.1038/s41408-021-00459-7. View

15.

Guo Y, Liu Y, Wu W, Ling D, Zhang Q, Zhao P . Indoleamine 2,3-dioxygenase (Ido) inhibitors and their nanomedicines for cancer immunotherapy. Biomaterials. 2021; 276:121018. DOI: 10.1016/j.biomaterials.2021.121018. View

16.

Lee S, Yang H, Kim W, Lee Y, Lee W, Kong S . STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer. J Immunother Cancer. 2021; 9(6). PMC: 8215239. DOI: 10.1136/jitc-2020-002195. View

17.

Miller B, Sen D, Al Abosy R, Bi K, Virkud Y, LaFleur M . Subsets of exhausted CD8 T cells differentially mediate tumor control and respond to checkpoint blockade. Nat Immunol. 2019; 20(3):326-336. PMC: 6673650. DOI: 10.1038/s41590-019-0312-6. View

18.

Lin J, Guo D, Liu H, Zhou W, Wang C, Muller I . The SETDB1-TRIM28 Complex Suppresses Antitumor Immunity. Cancer Immunol Res. 2021; 9(12):1413-1424. PMC: 8647838. DOI: 10.1158/2326-6066.CIR-21-0754. View

19.

Murthy A, Robinson N, Kumar S . Crosstalk between cGAS-STING signaling and cell death. Cell Death Differ. 2020; 27(11):2989-3003. PMC: 7560597. DOI: 10.1038/s41418-020-00624-8. View

20.

Gammelgaard K, Sandfeld-Paulsen B, Godsk S, Demuth C, Meldgaard P, Sorensen B . cGAS-STING pathway expression as a prognostic tool in NSCLC. Transl Lung Cancer Res. 2021; 10(1):340-354. PMC: 7867790. DOI: 10.21037/tlcr-20-524. View